Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo aberto para avaliar a segurança, eficácia e cinética celular do YTB323 em distúrbios autoimunes graves e refratários

14 de outubro de 2026 atualizado por: Novartis Pharmaceuticals

Um estudo aberto, multicêntrico, de fase 1/2 para avaliar a segurança, a eficácia e a cinética celular do YTB323 em participantes com distúrbios autoimunes graves e refratários

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

21

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Mainz, Alemanha, 55131
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Alemanha, 79106
        • Novartis Investigative Site
    • Victoria
      • Clayton, Victoria, Austrália, 3168
        • Novartis Investigative Site
      • Barcelona, Espanha, 08035
        • Novartis Investigative Site
      • Madrid, Espanha, 28009
        • Novartis Investigative Site
      • Paris, França, 75013
        • Novartis Investigative Site
      • Pessac, França, 33604
        • Novartis Investigative Site
      • Strasbourg, França, 67091
        • Novartis Investigative Site
      • Bern, Suíça, 3010
        • Novartis Investigative Site
      • Lausanne, Suíça, 1011
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Signed informed consent
  • Adequate renal, hepatic, cardiac, hematological and pulmonary function
  • Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE.
  • Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of ≥1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN)
  • Active (severe) disease as defined by SLEDAI-2K ≥ 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements:
  • Renal
  • At least moderate or severe peri/myocarditis
  • At least moderate or severe pleuritis or other lung involvement
  • Vasculitis
  • Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country).

Exclusion Criteria:

  • Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening.
  • Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy
  • Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis
  • Any patients requiring medications prohibited by the protocol
  • Any psychiatric condition or disability making compliance with treatment or informed consent impossible
  • Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy)
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation
  • Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion (or longer if required as per local regulations) and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome
  • Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient
  • B cell aplasia

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: YTB323

Single infusion of YTB323

Single infusion of YTB323

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of participants with AEs and SAEs
Prazo: Day 1 to 2 years

Long term safety follow up

Day 1 to 2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast)
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
Number of patients with anti-drug antibodies
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to measure anti-drug antibodies against YTB323.

Pre-dose, up to 2 years
Level of T cell activation by YTB323
Prazo: Pre-dose, up to 2 years

Blood samples will be collected to measure the level of T cell activation by YTB323.

Pre-dose, up to 2 years
Number of patients infused with planned target dose
Prazo: Day 1

Feasibility of the manufacturing process in autoimmune disorders.

Day 1
Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score
Prazo: Pre-dose, up to 2 years

SLEDAI-2K scores are between 0 and 105, a higher score represents a higher disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Physician's global assessment (PGA)
Prazo: Pre-dose, up to 2 years

The Physician's Global assessment is a visual analog scale from 0 to 3, 0 represents no activity and 3 represents severe disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS)
Prazo: Pre-dose, up to 2 years

LLDAS is a composite measure based on: SLEDAI-2K ≤ 4, with no activity in major organ system (renal, central nervous system, cardiopulmonary, vasculitis, and fever) and no hemolytic anemia or gastrointestinal activity, current, no new lupus disease activity compared with the previous assessment, prednisone (or its equivalent) dose ≤ 7.5 mg/day, PGA (scale 0-3) ≤ 1, well tolerated standard maintenance doses of immunosuppressive lupus therapy.

Pre-dose, up to 2 years
Remission rate
Prazo: Up to 2 years

Remission as specified by Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) criteria: Clinical SLEDAI=0, PGA<0.5 (0-3) irrespective of serology.

The patient may be on antimalarials, low-dose glucocorticoids (prednisolone ≤5 mg/day), and/or stable immunosuppressive therapy including biologics.

Up to 2 years
Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR)
Prazo: Pre-dose, up to 2 years

Change in the value of UPCR.

Pre-dose, up to 2 years
Incidence of Complete renal response (CRR)
Prazo: Up to 2 years

Number of participants who achieved CRR.

Up to 2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceutical

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de fevereiro de 2023

Conclusão Primária (Real)

24 de setembro de 2026

Conclusão do estudo (Real)

24 de setembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

27 de fevereiro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de março de 2023

Primeira postagem (Real)

4 de abril de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • CYTB323G12101
  • 2022-001796-14 (Número EudraCT)
  • 2023 (Concessão/Contrato do NIH dos EUA)
  • 2023-510081-27-00 (Outro identificador: EU CT number)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .